Five new IPOs are scheduled for the week of June 17th. The full IPO calendar is ipopremium.com/.
Ranked by size of IPO.
Votorantim Cimentos S.A. (VEBM), $3.4 billion
Based in São Paulo, SP, BR, Votorantim Cimentos S.A. scheduled a $3.4 billion IPO with a market capitalization of $53.7 billion at a price range mid-point of $17.05 per ADR, for Thursday, June 20, 2013.
VEBM is a cement and building materials company with operations in North and South America, Europe, Africa and Asia. Compared to both international and US cement and building materials companies, VEBM's price-to-sales, price-to-earnings (annualizing Q1 '13 results) and price-to-book values are much higher.
Gogo (NASDAQ:GOGO), $176 million
Based in Itasca, IL, Gogo scheduled a $176 million IPO with a market capitalization of $1.4 billion at a price range mid-point of $16, for Friday, June 21, 2013.
GOGO provides in-flight broadband services primarily to U.S. airlines.
Revenue increased 46% to $234 million for 2012 vs. 2011. Revenue was up 31% to $71 million for Q1 '1 vs. Q1 '12. But losses kept pace: $31 million loss in 2012 and $14 million in Q1 '13, compared with losses respectively of $24 million in 2011 and $4 million in Q1 '12. GOGO has 81% of the U.S. domestic market.
PTC Therapeutics (NASDAQ:PTCT), $100 million
Based in South Plainfield, NJ, PTC Therapeutics scheduled a $100 million IPO with a market capitalization of $322 million at a price range mid-point of $14.50 for Thursday, June 20, 2013.
PTCT is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Collaborations are on-going with Roche and the SMA Foundation for a spinal muscular atrophy program.
PTCT is developing its lead product Ataluren unilaterally. Altaluren targets Duchenne muscular dystrophy caused by nonsense mutations, or nmDMD, and cystic fibrosis caused by nonsense mutations, or nmCF. There is currently no marketed therapy approved for the treatment of either target.
Regado Biosciences (NASDAQ:RGDO), $75 million
Based in Basking Ridge, NJ, Regado Biosciences scheduled a $75 IPO with a market capitalization of $219 at a price range mid-point of $15, for Wednesday June 19, 2013.
RGDO is a biopharmaceutical company with an anticoagulant blood thinner that would, if approved, compete with blood thinners such as heparin.
The company plans to use the IPO funds to fund a Phase III clinical trial with 13,200 subjects, but RGDO has indicated no time estimate for completion. RDGO has no on-going collaborations.
bluebird bio (NASDAQ:BLUE)
Based in Cambridge, MA, bluebird bio scheduled a $75 million IPO with a market capitalization of $314 million at a price range mid-point of $15, for Wednesday, June 19, 2013.
BLUE is a biotech specializing in CAR T-cell therapy CAR T-cell therapy represents a promising, emerging approach to treating cancer.
In October 2012, BLUE was awarded a $9.3 million grant from the California Institute for Regenerative Medicine. In March 2013, BLUE entered into a strategic collaboration with Celgene (NASDAQ:CELG) to discover, develop and commercialize novel, disease-altering gene therapies in oncology. The CELG collaboration has an initial term of three years.